In MSDi cells, Tazarotene produced a dose-dependent significant increase in ARSA activity, with a reported EC50 of 4.9 μM. Tazarotene also increased GALNS activity in MSDi cells, with a reported EC50 of 2 μM. In B16 TRCs treated with Tazarotene at 100 µm for 24 h, the reported apoptosis finding was that 30–50% of TRCs became apoptotic when treated with ATRA, tazarotene, or cisplatin. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Tazarotene increases ARSA activity in MSDi cells
Cell-based study · MSDi cells [1]
MSDi cells treated with Tazarotene for 3 days showed a dose-dependent significant increase in ARSA activity compared with DMSO-only treatment. The reported EC50 was 4.9 μM.
Literature-Reported Treatment Conditions
- Treatment concentration
- as low as 2 μM
- Exposure duration
- 3 days
- Method
- applied to the cell culture medium
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Tazarotene
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Tazarotene and bexarotene effectively increase the activity of lysosomal sulfatases in immortalized MSD patient cells (S16, S17); Materials and Methods > Drug treatment (S159, S162); Figure EV1 legend (S337)
ARSA activity: ARSA activity; comparator: DMSO‐only treatment — Results > Tazarotene and bexarotene effectively increase the activity of lysosomal sulfatases in immortalized MSD patient cells (S16, S17)
Apoptosis in Tazarotene-treated TRCs
Cell-based study · B16 TRCs [2]
B16 TRCs were treated with Tazarotene at 100 µm for 24 h. The reported result was that 30–50% of TRCs became apoptotic when treated with ATRA, tazarotene, or cisplatin.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 µm
- Exposure duration
- 24 h
- Reported limits
- Not stated in the sentences used: route, vehicle, control.
Methods and source locations
Compound reported in the paper: Tazarotene
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Retinoid WYC‐209 Is Highly Potent in Inducing TRC Apoptosis (S3); Figure 1 legend (S166)
cell apoptotic ratio: cell apoptotic ratio — Results > Retinoid WYC‐209 Is Highly Potent in Inducing TRC Apoptosis (S3); Figure 1 legend (S166)
Tazarotene increases GALNS activity in MSDi cells
Cell-based study · MSDi cells [1]
MSDi cells treated with Tazarotene at 5 μM for 3 days showed increased GALNS activity. The reported EC50 was 2 μM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 3 days
- Method
- applied to the cell culture medium
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Tazarotene
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Tazarotene and bexarotene effectively increase the activity of lysosomal sulfatases in immortalized MSD patient cells (S17); Materials and Methods > Drug treatment (S159, S162); Figure 1 legend (S295); Figure EV1 legend (S339)
GALNS activity: GALNS activity; comparator: DMSO‐only treatment — Results > Tazarotene and bexarotene effectively increase the activity of lysosomal sulfatases in immortalized MSD patient cells (S17)